UPCC 25417: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
Brief description of study
Request for collaborative review: Sterling IRB serving as IRB of record.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Amyloidosis
-
Age: - 99 Years
-
Gender: All
Updated on
30 Jan 2020.
Study ID: 827805
